Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma

[1]  D. Barnes,et al.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ , 1991, Breast Cancer Research and Treatment.

[2]  T. Perren c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.

[3]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[4]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[5]  J. Bártková,et al.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.

[6]  P. V. van Diest,et al.  Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[7]  J. Bártková,et al.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.

[8]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[9]  B. Angus,et al.  c‐erbB‐2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study , 1990, Histopathology.

[10]  J. Bacus,et al.  HER-2/neu oncogene expression and proliferation in breast cancers. , 1990, The American journal of pathology.

[11]  S. Ashley,et al.  Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.

[12]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[13]  J. Bacus,et al.  HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.

[14]  A. Howell,et al.  C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. , 1990, British Journal of Cancer.

[15]  G. Hortobagyi,et al.  c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.

[16]  D. Barnes,et al.  An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple , 1989, Histopathology.

[17]  D. Barnes Breast cancer and a proto-oncogene. , 1989, BMJ.

[18]  P. Quirke,et al.  c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. , 1989, British Journal of Cancer.

[19]  J. Varley,et al.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.

[20]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Fernö,et al.  HER2/neu AMPLIFICATION AND COMEDO TYPE BREAST CARCINOMA , 1989, The Lancet.

[22]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[23]  J. Varley,et al.  An immunohistochemical and in situ hybridization study of c‐myc and c‐erbB‐2 expression in primary human breast carcinomas , 1989, The Journal of pathology.

[24]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[25]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[26]  M. Lagios,et al.  Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence , 1989, Cancer.

[27]  L. Skoog,et al.  Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. , 1989, European journal of cancer & clinical oncology.

[28]  T. Powles,et al.  Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer , 1988, International journal of cancer.

[29]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[30]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[31]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[32]  J. Meyer,et al.  Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations. , 1988, American journal of clinical pathology.

[33]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[34]  I. O. Ellis,et al.  Confirmation of a prognostic index in primary breast cancer. , 1987, British Journal of Cancer.

[35]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[36]  R. W. Baldwin,et al.  Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. , 1987, British Journal of Cancer.

[37]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[38]  M. Yoshida,et al.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line , 1986, Molecular and cellular biology.

[39]  M. Daidone,et al.  Cell kinetics as a prognostic marker in node‐negative breast cancer , 1985, Cancer.

[40]  I. Taylor,et al.  Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. , 1985, Cytometry.

[41]  W. Göhde,et al.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle , 1975, Radiation and environmental biophysics.

[42]  A. Schauer,et al.  c-erbB2 expression in correlation to other biological parameters of breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[43]  J. Meyer Cell kinetics of histologic variants ofin situ breast carcinoma , 2005, Breast Cancer Research and Treatment.

[44]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Visscher,et al.  Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. , 1990, Pathology annual.

[46]  W. Gullick Expression of the c-erbB-2 proto-oncogene protein in human breast cancer. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[47]  R. Cardiff Cellular and molecular aspects of neoplastic progression in the mammary gland. , 1988, European journal of cancer & clinical oncology.

[48]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[49]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[50]  R. Silvestrini,et al.  Cell proliferation and its relationship to clinical features and relapse in breast cancers. , 1981, Cancer.